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It has been hypothesized based on accumulated data that a class of small
noncoding RNAs, termed microRNAs, are key factors in intercellular com-
munication. Here, microRNAs present in interstitial breast tumor fluids
have been analyzed to identify relevant markers for a diagnosis of breast
cancer and to elucidate the cross-talk that exists among cells in a tumor
microenvironment. Matched tumor interstitial fluid samples (TIF, n = 60),
normal interstitial fluid samples (NIF, n = 51), corresponding tumor tissue
specimens (n = 54), and serum samples (n = 27) were collected from
patients with breast cancer, and detectable microRNAs were analyzed and
compared. In addition, serum data from 32 patients with breast cancer and
22 healthy controls were obtained for a validation study. To identify poten-
tial serum biomarkers of breast cancer, first the microRNA profiles of TIF
and NIF samples were compared. A total of 266 microRNAs were present
at higher level in the TIF samples as compared to normal counterparts.
Sixty-one of these microRNAs were present in > 75% of the serum samples
and were subsequently tested in a validation set. Seven of the 61 micro-
RNAs were associated with poor survival, while 23 were associated with
the presence of immune cells and adipocytes. To our knowledge, these data
demonstrate for the first time that profiling of microRNAs in TIF can
identify novel biomarkers for the prognostic classification and detection of
breast cancer. In addition, the present findings demonstrate that micro-
RNAs may represent the cross-talk that occurs between tumor cells and
their surrounding stroma.
Abbreviations
DFS, disease-free survival; ER, estrogen receptor; FDR, false discovery rate; FFPE, formalin-fixed paraffin-embedded; HER2, human
epidermal factor 2; IHC, immunohistochemistry; NIF, normal interstitial fluid; PgR, progesterone receptor; TAMs, tumor-associated
macrophages; TIF, tumor interstitial fluid; TILs, tumor-infiltrating lymphocytes; TLDA, TaqMan Low Density Arrays; TNBC, triple-negative
breast tumors.
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1. Introduction
Breast tumor heterogeneity in terms of morphology
and clinical outcome is well known, and these observa-
tions have mainly been based on pathology-driven
classifications of breast tumors. However, despite a
refinement of morphological subtyping of breast
tumors more than a decade ago, molecular classifica-
tions of breast tumors based on gene expression and/
or protein marker profiling are currently employed
(Perou et al., 2000; Prat and Perou, 2011). Consistent
with the heterogeneous pathology observed for breast
cancers on both molecular and cellular levels, recent
studies have revealed extensive genetic diversity within
the same breast cancer subtype, and each breast tumor
appears to have a unique molecular composition. Such
intertumor, or clonal, heterogeneity affects key cancer
pathways and drives phenotypic variations (Kao et al.,
2009; Mackay et al., 2009) while also presenting a sig-
nificant challenge in the treatment for breast cancer.
Breast cancer tumors are composed of a number of
different cells, including malignant cells, stromal com-
ponents, infiltrating host cells, and adjacent normal tis-
sue cells (de Visser et al., 2006). As such, the
heterogeneity in the tumor microenvironment, intratu-
mor heterogeneity, represents a major challenge to
efforts intended to identify tailored biomarkers for use
in clinical practice. Ideally, a blood-based test for
breast cancer detection would facilitate both diagnostic
and follow-up settings for clinicians as a supplement
to mammography. Thus, significant effort has been
invested to identify noninvasive biomarkers for the
diagnosis, prediction of therapy response, and progno-
sis of breast cancer (Bertoli et al., 2015).
A novel approach for breast cancer biomarker
research has recently been developed at the Danish
Cancer Society Research Center, and it involves the
collection and analysis of breast tumor interstitial fluid
(TIF; Gromov et al., 2013). Compounds detected in
interstitial fluid samples derive from all of the cells
present within a tumor mass, and contain signaling
molecules that underlie the interplay between tumor
cells and their microenvironment. It is hypothesized
that biomolecules such as microRNAs, lipids, and pro-
teins that are secreted by a tumor and stromal cells
into the interstitium are drained by the lymphatic sys-
tem and enter the bloodstream (Wagner and Wiig,
2015). Thus, these biomolecules could potentially be
detected and quantified. However, to date, no robust
blood markers for breast cancer have been identified.
It has been demonstrated and confirmed that the
spatial organization of multiple cell types within
tumors, including adipose cells, tumor-associated
macrophages (TAMs), and multiple tumor-infiltrating
lymphocytes (TILs), plays an essential role in tumor
development and drug responsiveness (Swartz et al.,
2012). Moreover, this organization is often reported to
impact prognosis (Salgado et al., 2015). For example,
high levels of TAMs are often associated with poor
prognosis in breast cancer (Ruffell et al., 2012).
Regarding TILs, a comprehensive meta-analysis found
that TILs only moderately affect cancer prognosis,
while the ratio of lymphocyte subgroups could poten-
tially be more informative (Gooden et al., 2011). Cor-
respondingly, different subtypes of leukocytes, such as
CD8+ cytotoxic T lymphocytes and CD4+ T-helper
cells, are often associated with good prognosis (Ruffell
et al., 2012), while anti-CD4+ cells, which can be a
marker for T regulatory cells, have been associated
with a less favorable prognosis in some cases (Li et al.,
2014).
microRNAs constitute a distinct class of small non-
coding RNAs that are recognized as gene expression
modulators. microRNAs have also been found to neg-
atively regulate numerous mRNAs by silencing their
target transcript (Ma and Weinberg, 2008). Accumu-
lating evidence indicates that the expression of micro-
RNAs in cancer and stromal cells during tumor
progression is altered (Soon and Kiaris, 2013). Fur-
thermore, several microRNAs are recognized to be
crucial regulators of immune cells. However, it remains
unclear whether microRNAs are pivotal to the com-
munication between tumor-associated immune cells
and tumor cells (Frediani and Fabbri, 2016; Kohlhapp
et al., 2015).
Recently, microRNAs have been examined in vari-
ous body fluids, including blood, saliva, urine, cere-
brospinal fluid, and breast milk. Each type of body
fluid exhibited a distinct microRNA pattern, which
potentially represents a tissue-specific profile (Weber
et al., 2010). Circulating microRNAs have been found
to be very stable, and tumor cells release a greater
number of microRNAs than normal cells (Riches
et al., 2014). Distinct alterations in microRNA expres-
sion profiles have also been observed during cancer
progression (Tahiri et al., 2014), thereby identifying
microRNAs as attractive molecules to serve as
biomarkers.
Until now, analyses of the molecular components of
TIF samples have been protein based (Celis et al.,
2004). In the present study, microRNAs in TIF
released from tumors were compared with microRNAs
released from normal mammary tissue (NIF) and
matched serum samples. The aim of the present study
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was to detect microRNAs that are secreted from
tumor and stromal cells in order to identify possible
serum-based microRNA biomarkers for breast cancer.
In addition, a correlation between elevated levels of
microRNAs in TIF samples and the presence of TILs
and adipocytes was observed. The present study con-
firms that breast tumor-associated microRNA-based
signatures are detectable in blood. Furthermore, the
role of microRNAs as mediators in the complex inter-
play between a tumor and the stromal environment
has been elucidated.
2. Materials and methods
2.1. Sample collection and handling
Tissue samples, including the tumor and corresponding
normal tissue distant from the tumor margin, were col-
lected by the Danish Center for Translational Breast
Cancer Research Program from clinical high-risk
patients (for criteria, see Doc S1) who underwent a mas-
tectomy between 2003 and 2012. None of the patients
had previously undergone surgery involving the breast
and they did not receive preoperative treatment. The
patients presented a unifocal tumor with an estimated
size > 20 mm. Patient survival, subsequently referred to
as disease-free survival (DFS), was measured from the
time of surgery until the date of first recurrence or the
date of death from breast cancer. If the patient remained
alive, or died due to other causes, the patient was cen-
sored. Death records up to December 31, 2013, were
included, and these were confirmed in the Danish Can-
cer Registration System and the Danish Register of
Causes of Death. Clinicopathological information was
provided by the Department of Pathology, Rigshospi-
talet, Copenhagen University Hospital. This study was
conducted in compliance with the Helsinki II Declara-
tion, and written informed consent was obtained from
all participants. This project was approved by the
Copenhagen and Frederiksberg regional division of the
Danish National Committee on Biomedical Research
Ethics (KF 01-069/03).
Each tissue specimen was divided into two pieces.
One tissue piece was stored at 80 °C and was later
used for microRNA extraction and the preparation of
formalin-fixed and paraffin-embedded (FFPE) blocks
for histological characterization, tumor subtyping, and
scoring of TILs. The second tissue piece was used for
interstitial fluid recovery (TIF and NIF) and was
stored in PBS buffer at 4 °C within a maximum of
45 min from the time of surgical excision. Blood sam-
ples were collected preoperatively according to a stan-
dardized protocol (Wurtz et al., 2008).
2.2. Sample characterization, breast tumor
subtyping, and scoring of TILs
Immunohistochemistry (IHC) was performed as previ-
ously described to fulfill histological characterizations
(Gromov et al., 2010). The first and last sections of
each FFPE sample were stained with a CK19 antibody
to verify tumor cell content and the number of mam-
mary epithelial glands (Gromov et al., 2010). A visual
assessment of tumor stroma percentage, as well as the
proportion of adipose tissue, was evaluated as previ-
ously described (Mesker et al., 2007). Slides were
reviewed by two blinded researchers (IIG and PSG).
Subtype scoring of luminal A, luminal B, HER2, and
triple-negative tumors (TNBC) was performed based
on estrogen receptor (ER), progesterone receptor
(PgR), human epidermal receptor-2 (HER2), and Ki67
status in accordance with St. Gallen International
Breast Cancer Guidelines (Esposito et al., 2015)
(Table S1). An overview of the samples examined and
the tumor subtypes identified are listed in Tables 1
and S2. The antibodies used for ER, PgR, HER2, and
Table 1. Stratification of samples analyzed in this study according
to tumor subtype, grade, and ER, PgR, and HER2 status. Scoring
of the clinical features for the TIF, NIF, and serum samples refers
to the corresponding tumor material. NIF, normal interstitial fluid;
TIF, tumor interstitial fluid; ER, estrogen receptor; PgR,
progesterone receptor; HER2, human epidermal factor 2.
Tumor TIF NIF Serum P valuea
Number of cases 54 60 51 27
Subtype
Lum A 24 25 23 12 0.98
Lum B 12 14 13 6
HER2 7 8 4 4
TNBC 11 13 11 5
ER status
ER positive 37 40 37 18 0.95
ER negative 17 20 14 9
PgR status
PgR positive 27 29 26 13 0.99
PgR negative 25 28 22 13
No data 2 3 3 1
HER2 status
0 17 17 13 8 0.99
1+ 16 19 18 10
2+ 13 15 15 4
3+ 8 9 5 5
Grade
Grade 1 4 4 4 0 0.53
Grade 2 22 24 21 10
Grade 3 26 30 24 17
No data 2 2 2 0
aKruskal–Wallis test.
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Ki67 scoring are listed in Table S3. The proportion of
TILs in direct contact with the tumors was evaluated
by IHC in accordance with the recommendations of
the International TILs Working Group 2014 (Salgado
et al., 2015). Scoring of total TILs (1+ to 3+) was per-
formed based on an evaluation of the sections stained
by hematoxylin and eosin (HE) with the following cat-
egories: 1+ – ≤ 10%; 2+ – 10–50%; and 3+ – > 50%
of the cells stained. Scoring of total leukocytes, T lym-
phocytes, T-helper lymphocytes, cytotoxic T lympho-
cytes, and macrophages was determined based on
staining performed with antibodies raised against
CD45+, CD3+, CD4+, CD8+, and CD68+, respec-
tively. In Fig. S1, an example of the leukocyte evalua-
tion that was performed with the most common CD
markers is shown. Only antibodies whose specificity
was previously evaluated in a number of published
studies were used (see Table S3).
2.3. Preparation of breast TIF and NIF samples
TIF and NIF samples were extracted from surgically
resected small pieces of breast tumor and normal tissue
that were collected as mastectomy specimens as previ-
ously described (Celis et al., 2004). Briefly, each
resected, clean fresh tissue sample (0.2–0.3 g, as it was
evaluated in our previous study) (Celis et al., 2004)
was cut into small pieces (1 mm3), washed twice with
cold PBS to remove traces of blood and cell debris,
and placed in a 10-mL conical plastic tube containing
1.0 mL of PBS. Samples were incubated for 1 h at
37 °C in a humidified CO2 incubator. Thereafter, the
samples were centrifuged at 300 g for 2 min, and the
supernatant was aspirated with the aid of an elongated
Pasteur pipette. Samples were further centrifuged at
4000 g for 20 min in a refrigerated centrifuge (4 °C).
These sequential centrifugations greatly facilitate
removal of debris. Supernatants were collected and
total protein concentrations for each sample were
determined with the Bradford assay (Bradford, 1976).
Only tumor specimens with 0.2–0.3 g were used for
TIF recovery.
2.4. microRNA profiling
Due to the low abundance of microRNAs in the NIF
and serum samples, TaqMan Low Density Arrays
(TLDA, cat# 4444913; Applied Biosystems, Foster
City, CA, USA) were used. A total of 754 unique
microRNAs were analyzed in the 60 TIF, 51 NIF, and
27 matched serum samples. Additionally, 54 tumor
samples and corresponding TIFs isolated from 14 of
these tumor samples were selected to undergo further
analysis on high-density hybridization arrays with
2549 human microRNAs represented (based on miR-
Base database release 21, Human microRNA Microar-
rays, 8x60K, v.21, G4872A; Agilent Technologies,
Santa Clara, CA, USA). For details, see Doc S1.
2.5. Data normalization
Data generated from the TLDA cards were normalized
per sample using global normalization (Mestdagh et al.,
2009), and the expression of each microRNA was mean-
centered using only expressed microRNAs. Nondeter-
mined values were replaced with the lowest value
detected on a linear scale (Stahlberg et al., 2013). For
normalization of the data generated from the hybridiza-
tion arrays, the 90th percentile was calculated for each
array, and then, this value was subtracted from each
value on the array before baseline correction and a log2
transformation were applied (Gene Spring, v.13 Agilent
Technologies). For details, see Doc S1.
2.6. Statistical analysis
R version 3.2.1 was utilized for statistical analyses. The
Wilcoxon rank-sum test was used for testing differen-
tial expression, and a false discovery rate (FDR)
< 0.01 was considered significant. Multiple compar-
isons between subtypes were made using the Kruskal–
Wallis analysis of variance (ANOVA) test for the iden-
tification of differentially expressed microRNAs across
the subtypes. Univariate and multivariate regression
analyses were performed to evaluate associations
between CD3+, CD4+, CD45+, CD8+, and CD68+
lymphocytes, adipocytes, and the level of microRNAs
in TIF. Spearman’s rank correlation analysis was used
to assess the association between microRNA levels
across different cellular components. The log-rank test
with Kaplan–Meier plots was used for univariate sur-
vival analysis, while Cox regression was conducted for
multivariate survival analysis. The differential abun-
dance of 61 microRNAs detected in serum was vali-
dated in an independent cohort of Chinese patients
with breast cancer (n = 32) and healthy controls
(n = 22) that were retrieved from Gene Expression
Omnibus (accession number: GSE42128) (Chan et al.,
2013). Unsupervised hierarchical clustering was per-
formed using Spearman’s rank correlation analysis and
average linkage in JEXPRESS (Dysvik and Jonassen,
2001). For pathway analysis, QIAGEN’s Ingenuity
Pathway Analysis (QIAGEN, Redwood City, www.qi
agen.com/ingenuity) was utilized. A FDR < 0.05 was
considered significant. More details are provided in
Doc S1.
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3. Results
3.1. Comparative microRNA profiling of TIF, NIF,
serum, and tumor tissue samples
The numbers of microRNAs present in more than
30% of the TIF, NIF, and corresponding serum sam-
ples were 457, 184, and 201, respectively (Fig. S2).
Two microRNAs were detected exclusively in the NIF
samples, eight microRNAs were unique to the serum
samples, and 218 microRNAs were only detected in
the TIF samples. A total of 343 microRNAs were pre-
sent in more than 30% of all three sample types (data
not shown).
To compare the microRNA profiles of the tumor,
TIF, NIF, and serum samples, Spearman’s rank cor-
relation analysis was performed. Because the correla-
tion of low abundant microRNAs was also of
interest, none of the microRNAs were filtered out
(n = 754 in TLDA and n = 730 in hybridization
arrays). The highest number of correlated micro-
RNAs was found between the tumor and TIF
samples (n = 62) and between the TIF and NIF
samples (n = 61). Fewer microRNAs correlated with
serum (n = 48 for TIF and n = 39 for NIF). All of
the microRNAs that exhibited a significant correla-
tion (P < 0.05) between the different sample types
are listed in Table S4.
3.2. Detection of 61 unique microRNAs in TIF
samples: candidate breast cancer biomarkers in
serum
To identify tumor-associated biomarkers in serum, we
selected microRNAs present in high abundance in TIF
samples relative to NIF samples and with measurable
levels in serum. The Wilcoxon rank-sum test identified
266 microRNAs with a significantly higher abundance
in TIF samples relative to NIF samples (FDR < 0.01,
Table S5). Of these, 61 microRNAs were detected in
more than 75% of the serum samples (Table S6 and
Doc S1), and these represent potential serum biomar-
ker candidates. An overview of the biomarker search
that was conducted is presented in Fig. 1.
Fig. 1. Flowchart of the strategy used to identify breast cancer biomarkers. First, microRNAs with significantly higher abundance in TIF
samples compared to NIF samples were identified (n = 266). Of these, 61 microRNAs were detected in > 75% of serum samples and are
referred to as potential biomarker candidates. Fifty-two of the 61 candidates exhibited a higher abundance in tumor tissue samples than in
TIF samples. In addition, 16 of these 52 microRNAs had a higher abundance in the serum of patients with breast cancer compared to
controls in an independent dataset. In the two upper right panels, the expression levels of the 61 candidates identified in the TIF samples
were examined for their association with TILs, adipocytes, and DFS. Twenty-three microRNA candidates were associated with tumor
infiltration of TILs or the presence of adipocytes, while seven microRNAs were associated with DFS. In the two lower right panels, the 16
validated microRNAs were associated with cellular components within a tumor mass (TILs) and were correlated with DFS. TILs, tumor-
infiltrating lymphocytes; DFS, disease-free survival; NIF, normal interstitial fluid; TIF, tumor interstitial fluid.
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To reveal a possible association between the 61
microRNAs that were detected in TIF and serum sam-
ples with their corresponding intracellular levels, we
compared the microRNA profiles of tumor samples
and matched TIF samples on hybridization arrays.
Three of the 61 microRNAs were not included on the
array and six of the microRNAs did not significantly
differ. However, 52 of the microRNAs assayed were
significantly elevated in the tumor samples compared
with the TIF samples (FDR < 0.01, Table S7).
To evaluate the potential clinical relevance of these
61 microRNAs identified as candidates for a blood-
based prognostic test, Kaplan–Meier survival analyses
were performed for all of the serum samples to identify
microRNAs that might correlate with DFS. Of the 61
candidates present in the serum samples, seven of the
microRNAs (miR-126-5p, miR-1274b, miR-1825, miR-
195-5p, miR-20b-5p, miR-454-3p, and miR-miR-93-
5p) were found to be significantly related to DFS
(Fig. 2). Because our dataset did not include samples
from healthy controls, all 61 microRNAs were evalu-
ated in an independent Asian breast cancer serum
cohort (Chan et al., 2013). Of the 61 candidates, nine
of the microRNAs were not assessed in the Asian
dataset. Of the 52 remaining microRNAs, 16 (miR-16,
miR-17, miR-195, miR-19a, miR-20b, miR-210, miR-
25, miR-30a, miR-30d, miR-320a, miR-378, miR-425,
miR-484, miR-574-3p, miR-92a, and miR-93) were sig-
nificantly more abundant in the serum of patients with
breast cancer relative to the healthy controls
(FDR < 0.05, Table S8). For visualization, the relative
abundance of the 16 validated microRNAs in TIF,
NIF, and serum samples is illustrated with a heatmap
in Fig. S3. Three of the microRNAs, miR-195-5p,
miR-20b-5p, and miR-93-5p, were also associated with
DFS when analyzed in our cohort (Figs 1 and 2).
3.3. microRNAs in the tumor interstitium are
associated with breast tumor subtype and TILs
To elucidate the cellular origin of the microRNAs
identified in the TIF samples, a multivariate regression
analysis was conducted to examine the proportion of
tumor cells, the presence of adipocytes, and the pres-
ence of various TIL subtypes associated with each TIF
microRNA. Of the 457 microRNAs that were ana-
lyzed, the proportion of tumor cells and the presence
of TILs were two factors that significantly contributed
to the variations observed for 179 of these microRNAs
(FDR < 0.05, Table S9). In a univariate regression
analysis, the proportion of TILs and the presence of
adipocytes were the factors that significantly con-
tributed to the variations observed in 23 of the 61
microRNA candidates examined (Table 2 and Fig. 1).
For miR-142-3p, 28% of its variation could be
explained by the presence of TILs. Moreover, depend-
ing on the type of lymphocytes present, the range of
variation was 16–23%. The levels of mir-454-3p, miR-
20b-5p, and miR-93-5p significantly correlated with
the presence of TILs. Furthermore, high levels of these
microRNAs in serum were associated with a worse
prognosis (Fig. 1). Regarding the presence of miR-93-
5p in the TIF samples, its levels significantly correlated
with its expression in tumors and with the presence of
adipocytes within a tumor mass. A possible scenario
for microRNA interactions between tumor cells and
stromal cells is shown in Fig. 3. Four microRNAs cor-
related with the presence of TILs and also exhibited
significantly higher expression levels in the serum of
patients with breast cancer relative to healthy controls.
These microRNAs were miR-17, miR-20b, miR-30d,
and miR-93 (Fig. 1).
To identify pathways potentially altered by the
microRNAs that positively correlated with the pres-
ence of TILs, an ingenuity pathway analysis was con-
ducted. Pathway analyses were also conducted for the
microRNAs that correlated with an infiltration of adi-
pocytes and specific types of lymphocytes (including
CD3+, CD4+, CD45+, CD8+, and CD68+ lympho-
cytes) (Table S10). The pathway, ‘Molecular Mecha-
nism of Cancer’, was found to be altered for the
microRNAs that correlated with the presence of
CD3+, CD45+, CD8+, and CD68+ lymphocytes as
well as infiltrating adipocytes, but not CD4+ lympho-
cytes.
To study whether a correlation exists between TIF
microRNAs and parameters such as subtype and hor-
mone receptor status, unsupervised hierarchical clus-
tering with Spearman’s rank correlation and average
linkage was performed for all 457 microRNAs
(Fig. 4). The 60 TIF samples clustered into two main
groups. The TNBC samples primarily clustered into
one subgroup of the first main cluster. The luminal A
samples were distributed between both clusters. A
greater number of ER- and PgR-negative samples, as
well as a higher proportion of TILs, were present in
cluster 1. Furthermore, according to the log-rank test,
patients in cluster 1 experienced a longer DFS period
(P = 0.058) (Fig. S4A). When the data were stratified
into subtypes, only the luminal A subtype exhibited a
significant better survival in cluster 1 (Fig. S4B). The
parameters, tumor grade, patient age, and tumor
stage and size did not significantly differ between clus-
ters 1 and 2. However, a tendency for grade 3 samples
to be in cluster 1 was observed (P = 0.082, logistic
regression).
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In the two main microRNA clusters that were iden-
tified, there were several subclusters of microRNAs
within each. Four of the microRNA subclusters were
enriched with microRNAs associated with adipocyte-,
TIL-, CD68-, and CD4-associated microRNAs. The
microRNA cluster that was associated with CD68+
cells was enriched with microRNAs from the miR-17-
92 family.
To identify subtype-specific microRNAs across the
TIF samples, the Kruskal–Wallis test and Wilcoxon
rank-sum test were performed for all 457 microRNAs
(P < 0.05, Tables 3 and S11). Three of the micro-
RNAs (miR-190b, miR-375, and miR-376a-5p) had an
FDR < 0.05 and four microRNAs (miR-190b, miR-
224-5p, miR-342-3p, and miR-376a-5p) exhibited sig-
nificantly different levels in luminal samples versus
Fig. 2. Kaplan–Meier curves for microRNAs whose abundance in serum was associated with time to recurrence. The green and red curves
represent the abundance under and above the median, respectively.
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HER2-positive and TNBC samples. In addition, com-
pared with all other subtypes, miR-671-3p and 342-5p
showed significantly different abundance in HER2-
positive samples, miR-1281 had a lower level in the
luminal A samples, and miR-524-3p was found at
lower level in the luminal B samples. Four of the sub-
type-specific microRNAs detected in TIF (miR-342-3p,
miR-342-5p, miR-224-5p, and miR-375) showed
positive correlation with the abundance of the same
microRNA in the tumor samples. One of these (miR-
342-3p) was correlated with the level in serum as well.
Two (miR-375 and miR-27a-5p) of the microRNAs
with high abundance in the luminal A and HER2-posi-
tive samples were associated with poor prognosis.
4. Discussion
4.1. Identification of putative diagnostic and
prognostic microRNA biomarker candidates for
breast cancer
To our knowledge, this is the first study to investigate
microRNAs present in TIF with the goal of identifying
noninvasive diagnostic markers for breast cancer. A
total of 61 microRNAs were present in greater abun-
dance in TIF samples than in NIF samples and were
also present in > 75% of the serum samples. Higher
levels of expression were also observed for 51 of these
61 candidates in tumor samples compared to TIF sam-
ples, thereby supporting the hypothesis that these are
tumor-derived microRNAs. These findings confirm the
concept that fluid proximal to a primary tumor is a
promising source for disease biomarkers, and they also
demonstrate the ability of our approach to identify
potential serum biomarkers of breast cancer. Further,
the low number of correlated microRNAs between
tumor and TIF supports that TIF contains mainly
secreted miRNAs without major contamination from
intracellular molecules. This is previously demon-
strated at the protein level, where mass spectrometry
showed absence of intracellular proteins like keratins
and nuclear proteins (Celis et al., 2004; Gromov et al.,
2010). To validate these data, 52 of the 61 microRNAs
were tested against an independent set of serum sam-
ples obtained from a Chinese cohort of patients with
breast cancer and healthy individuals. Sixteen of the
Table 2. Univariate regression analysis revealed that the presence of TILs and adipocytes significantly contributed to the variation observed
for 23 microRNAs in an independent manner. The microRNAs are listed alphabetically. Antibodies against CD45+, CD3+, CD4+, CD8+, and
CD68+ were used to determine total leukocytes, T lymphocytes, T-helper lymphocytes, cytotoxic T lymphocytes, and macrophages,
respectively. TILs, tumor-infiltrating lymphocytes; ns, not significant. Values with P < 0.05 (P) are listed in the table with their Spearman’s
rank correlation values (R). R-values ≥ 0.20 are shown in boldface.
miRNA
TIL CD 68 CD 8 CD 4 CD 3 Adipose
P-value R P-value R P-value R P-value R P-value R P-value R
let-7e-5p 0.05 0.06 ns ns ns ns ns ns ns ns ns ns
miR-140-5p ns ns ns ns ns ns 0.03 0.17 ns ns ns ns
miR-142-3p 0.00 0.28 0.02 0.20 0.03 0.18 0.01 0.23 0.05 0.16 ns ns
miR-146a-5p 0.03 0.08 ns ns ns ns ns ns ns ns ns ns
miR-146b-5p 0.00 0.19 ns ns ns ns 0.02 0.19 ns ns ns ns
miR-151a-3p 0.03 0.08 0.02 0.20 ns ns ns ns ns ns 0.00 0.24
miR-17-5p 0.01 0.10 0.02 0.20 ns ns ns ns 0.02 0.19 ns ns
miR-20b-5p 0.03 0.08 ns ns ns ns ns ns ns ns ns ns
miR-21-5p ns ns ns ns ns ns ns ns ns ns 0.03 0.18
miR-221-3p ns ns ns ns ns ns ns ns ns ns 0.01 0.23
miR-222-3p 0.04 0.07 ns ns 0.04 0.16 0.01 0.21 ns ns ns ns
miR-223-3p 0.00 0.14 ns ns ns ns ns ns 0.03 0.17 ns ns
miR-223-5p 0.01 0.13 ns ns ns ns ns ns 0.04 0.17 ns ns
miR-27a-3p 0.00 0.17 0.05 0.16 ns ns ns ns ns ns ns ns
miR-29a-3p ns ns ns ns ns ns 0.02 0.20 ns ns ns ns
miR-30d-5p ns ns ns ns ns ns ns ns ns ns 0.04 0.17
miR-301a-5p 0.05 0.06 0.02 0.20 ns ns ns ns ns ns ns ns
miR-324-3p ns ns ns ns ns ns ns ns ns ns 0.04 0.17
miR-345-5p 0.04 0.07 ns ns ns ns ns ns ns ns 0.05 0.16
miR-374a-5p 0.02 0.09 ns ns ns ns ns ns ns ns ns ns
miR-454-3p 0.01 0.13 0.03 0.18 ns ns ns ns ns ns ns ns
miR-885-5p ns ns ns ns ns ns 0.03 0.18 ns ns ns ns
miR-93-5p 0.04 0.07 ns ns ns ns ns ns ns ns 0.04 0.16
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microRNAs were subsequently identified as potential
noninvasive breast cancer biomarkers. Interestingly,
several of these 16 validated microRNAs have previ-
ously been proposed to represent prognostic or diag-
nostic biomarkers for breast cancer. These include
miR-210 (Volinia et al., 2012), miR-195 (Heneghan
et al., 2010), miR-20b (Zhou et al., 2014), and miR-
484 (Zearo et al., 2014). Our results also showed that
high levels of miR-93, miR-195, and miR-20b were
associated with poor DFS, while the levels of miR-20b
and miR-93 in the TIF samples correlated with the
presence and type of TILs present. In general, TILs
are accepted as prognostic factors for breast cancer
(Savas et al., 2015). The importance of TILs and other
components of breast cancer microenvironment as
clinically relevant biomarkers reinforces by an Interna-
tional TILs Working Group created in 2014 (Salgado
et al., 2015). However, as a relatively small number of
matched serum samples (n = 27) were included in the
present study, further studies need to be conducted
with larger groups of patients to confirm these find-
ings. In addition, it is possible that the small number
of matched serum samples prevented the identification
of other relevant microRNAs.
4.2. microRNAs in the interstitium are associated
with patient survival and reflect breast cancer
subtypes
Unsupervised hierarchical clustering revealed two main
clusters for the TIF samples examined in this study.
Cluster 1 was enriched with hormone receptor-negative
(e.g., ER-, PgR-, and HER2-) and samples with high
TILs, which suggests that microRNAs detected in the
interstitium are associated with breast tumor subtype,
as well as immune response. Interestingly, cluster 1
also revealed a higher abundance of the microRNAs.
This was especially pronounced for microRNAs asso-
ciated with the presence of TILs. This is in line with
the growing evidence of immunology as a central part
of the tumor biology and outcome (Salgado et al.,
2015). The two main sample clusters that were identi-
fied represented different disease courses, and a signifi-
cantly better outcome was observed for the patients in
Fig. 3. microRNAs in TIF and serum that correlate with the presence of immune cells, adipocytes, and tumor cells. These microRNAs are
most likely involved in the cross-talk between tumor cells and the microenvironment. TIF, tumor interstitial fluid.
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cluster 1. These data imply that microRNAs that are
detected in the TIF and originate from both cancer
cells and stromal cells may reflect biological processes
that are associated with prognosis. Unexpectedly, how-
ever, cluster 1 also included a subcluster of TNBC
samples, and the association between TNBC tumors
and poor prognosis is well known. This subcluster of
samples was also associated with a high number of
TILs, which is a characteristic often associated with
improved survival, especially in TNBC- and HER2-
positive patients (Savas et al., 2015). The difference in
survival between the two clusters was particularly pro-
nounced for the luminal A samples. In particular, two
microRNAs, miR-27a-5p and miR-375 whose
Fig. 4. Unsupervised hierarchical clustering of microRNA abundance in 60 TIF samples resulted in the identification of two main clusters.
Clinical parameters are indicated to the left of each cluster. In the heatmap, high abundance and low abundance of microRNAs are
represented with dark blue and pink colorings, respectively. Missing values are shown in white, indicating that the microRNA was not
detected in the TIF sample. Four subclusters enriched with microRNAs associated with TILs and adipocytes were identified and are
indicated with a red frame. The microRNAs within the four clusters are listed to the right.
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overexpression was related to unfavorable survival,
exhibited significantly higher levels in luminal A and
HER2-positive samples relative to luminal B and
TNBC samples. In addition, the level of miR-375 in
TIF was found to positively correlate with the percent-
age of a tumor, yet the same correlation was not
observed for serum samples. In a study of metastatic
breast cancer, high levels of miR-375 in serum were
significantly correlated with poor survival (Madhavan
et al., 2016). Due to the small number of samples in
each subgroup, our survival analysis should be inter-
preted with caution and additional studies with a
greater number of samples are needed to further inves-
tigate these findings.
Recently, a number of specific microRNAs have
been reported elevated in breast carcinomas (van
Schooneveld et al., 2015), but not previously been
investigated in interstitial fluids. In the present study,
miR-190b was found at higher levels in luminal A and
luminal B samples compared with HER2 and TNBC
samples, while TNBC samples contained higher levels
of miR-9-5p compared with the luminal samples. Pre-
viously, lower levels of miR-190b and higher levels of
miR-9 were detected in TNBC tumor biopsies (Volinia
et al., 2012). Similarly, another study reported that
miR-190b was up-regulated in luminal tumor samples
compared with TNBC and HER2 tumor samples, and
miR-9 was only expressed in TNBC tumor samples
and not in other subtype samples (Enerly et al., 2011).
The level of miR-190b and miR-9 TIF did not corre-
late with the level detected in tumor in our project. On
the other hand, four of the subtype-specific micro-
RNAs detected in TIF were correlated with the level
in tumor tissue (miR-342-3p, miR-342-5p, miR-224-5p,
and miR-375). miR-342-3p was found more abundant
in the TIF of luminal samples compared to HER2 and
TNBC. In addition, the distribution was correlated
both in the tumor samples and in the serum samples.
Taken together, these results indicate that only a por-
tion of the subtype-specific microRNAs produced in a
tumor may be released into the interstitium. Further,
very few of these specific microRNAs can be detected
in serum.
4.3. The presence of TILs, adipocytes, and tumor
cells affects microRNAs
Of all the microRNAs detected in the TIF samples
(n = 457), 179 were present at levels that were associ-
ated with the type of TILs present and the proportion
of tumor cells in the corresponding tumor sample.
Among the 61 candidate biomarkers identified, the
presence of TILs or adipocytes influenced the varia-
tion observed for 23 of these microRNAs. When hier-
archical clustering of the TIL-associated microRNAs
was performed, the subgroups identified were found to
be enriched with microRNAs associated with CD4+
(used as a marker for T-helper lymphocytes) and
CD68+ (a marker for macrophage) cells (Fig. 4). In
particular, miR-223 was significantly correlated with
CD3+ (a general marker of lymphocytes) and CD45+
(a pan-leukocyte marker) cells. In another study,
miR-223 was detected in exosomes released from
macrophages that were shuttled to co-cultivated breast
cancer cells, and this resulted in an in vitro invasion of
breast cancer cells (Yang et al., 2011). miR-223, miR-
146, let-7e, and miR-21 have also been identified as
key factors for macrophage activation (Squadrito
et al., 2013). Macrophages can be classified as classi-
cally activated (M1) or alternatively activated (M2).
The latter promote an anti-inflammatory response
(Noy and Pollard, 2014) and are also referred to as
TAMs. In a recent study of breast cancer, miR-223
and miR-146a were present at lower levels in TAMs,
which suggested that these microRNAs play a role in
regulating M2 polarization (Li et al., 2015). In the
present study, miR-142-3p expression is highly corre-
lated with TILs and with each subgroup of CD3+,
CD4+, CD45+, CD68+, and CD8+ cells (with CD8+
used as a marker of cytotoxic T lymphocytes). These
results are consistent with a report where miR-142-3p
is highly expressed in T cells (Wu et al., 2007). Fur-
thermore, up-regulation of miR-142-3p has been
reported to impair macrophage differentiation and to
increase CD8+ cell proliferation, which resulted in less
immunosuppressive activity (Sonda et al., 2013). It
Table 3. microRNAs (n = 12) in TIF significantly associated with
breast cancer subtypes. Higher abundance of miR-27a-5p and miR-
375 was associated with shorter DFS periods. DFS, disease-free
survival; TIF, tumor interstitial fluid.
LumA LumB HER2 TNBC
miR-1282 Down Up Up Up
miR-190b Upa Up Down Downa
miR-224-5p Down Down Up Up
miR-27a-5pb Up Down Up ns
miR-342-3p Up Up Down Down
miR-342-5p Up Up Down Up
miR-375b Upa ns Up Downa
miR-376a-5p Upa Up Down Downa
miR-432-3p Down Up Down Up
miR-524-3p Up Down Up Up
miR-671-3p Down Down Up Down
miR-9-5p Down Down ns Up
aFDR < 0.05.
bHigh level associated with decreased DFS.
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would be interesting to investigate which miRNAs are
specifically originated from different TILs subtypes;
however, such a project represents an independent and
rather extensive study and is therefore beyond the
scope of the present study.
The miR-17/92 cluster, which is comprised of
miR-17, miR-18a, miR-19a, miR-19b, miR-20a, and
miR-92, is probably one of the most studied onco-miR
clusters to date (Mogilyansky and Rigoutsos, 2013).
miR-17 has been found to regulate the proliferation of
CD8+ T cells (Khan et al., 2013) and to play a role in
macrophage infiltration and cytokine secretion (Zhu
et al., 2013). In the present study, CD68-associated
microRNAs were identified in the same cluster as the
17/92 onco-miRs. In addition, miR-17 positively corre-
lated with the presence of CD68+ cells. miR-17, miR-
19a, and miR-92 were also among the 61 microRNA
candidates that were validated in an independent
breast cancer cohort. Based on these data, we hypothe-
size that a subset of the 16 validated microRNAs in
serum are directly involved in the interplay between
tumor cells and immune cells. Moreover, we find that
several of the TIL-correlated microRNAs identified
(see Table 2) appear to have an active role in either
pro-inflammatory or anti-inflammatory responses, and
this reflects the communication that occurs between
compartments present in the tumor stroma. Corre-
spondingly, cancer-associated cells and immune cells
have previously been shown to contribute to a reactive
stroma in response to a tumor (Tjomsland et al.,
2011).
The pathway termed, ‘Molecular Mechanisms of
Cancer’, by QIAGEN’s Ingenuity Pathway Analysis
program includes molecular components that poten-
tially mediate inter- and intracellular communication
that results in a malignant phenotype. This pathway
was predicted to be affected by the presence of micro-
RNAs that correlate with CD3+, CD45+, CD8+, and
CD68+ lymphocytes, as well as infiltrating adipocytes.
Similarly, microRNAs associated with TILs and
CD4+ cells were enriched within the pathway termed,
‘Role of Macrophage, Fibroblasts, and Endothelial
Cells in Rheumatoid Arthritis’. This pathway involves
the activation of T cells, synovial fibroblasts, and
macrophage, which leads to altered T-cell and B-cell
signaling. The top canonical pathways predicted to be
altered were similar for many of the TIL subgroups
and this may be because these pathways are associated
with many of the microRNAs that exhibited a higher
abundance in the TIF samples compared with the NIF
samples. Moreover, these abundant microRNAs may
participate in some of the same processes encompassed
by these pathways.
4.4. microRNAs present in TIF and serum
samples as candidate blood-based biomarkers
In the present study, the levels of microRNAs that
were detected in the TIF and NIF samples were very
different. Moreover, only a subset of the microRNAs
with high abundance in the TIF samples were also
detected in serum. The latter observation highlights
the challenges associated with identifying blood-based
biomarkers, particularly because microRNAs derived
from tumor cells are diluted in blood which also car-
ries molecules from other cells in the body. For exam-
ple, blood cells contribute microRNAs to the systemic
circulation, and it has been suggested that the majority
of microRNAs found in serum derive from platelets
undergoing activation (Gyorgy et al., 2011). Thus, in
the present study, we focused on detecting microRNAs
present in TIF and serum in order to identify tumor-
related serum microRNAs. However, we anticipated
that this subset of microRNAs would be diluted in
serum and therefore would not be readily detected. To
address this limitation, it may be important to use sev-
eral microRNAs as biomarkers in order to strengthen
the predictive power (Cui et al., 2015). So far 16
microRNAs were identified as putative blood-based
markers of breast cancer in the present study.
It is also important to note that these 16 micro-
RNAs were identified and validated despite the exis-
tence of factors that are not directly related to cancer,
yet can affect microRNA detection. For example, the
collection and processing methods used for samples,
the type of analytical platform employed, normaliza-
tion of data, tumor stage, tumor grade, and/or patient
ethnicity can all affect the microRNA profile of blood
samples (Cui et al., 2015). Thus, the 16 microRNAs
identified and validated appear to be robust biomark-
ers and they should be further evaluated for their
capacity to indicate the presence of breast cancer.
Given that the tumor microenvironment is com-
posed of various cells with different origins, such as
immunological cells, only a portion of detected micro-
RNAs may derive directly from tumor cells. micro-
RNAs can regulate numerous processes and affect
different mRNAs. This makes the backtracking of
microRNAs to specific cells particularly challenging.
In vitro experiments could link individual miRNAs to
specific cell types, but can hardly encompass the com-
plexity of a living tumor. As a diagnostic tool, a panel
of microRNAs will most likely increase the robustness
of integrative molecular signatures that can be used as
the diagnostic markers. It is also possible that some
microRNAs remain associated with the local intersti-
tium, while others are able to access the circulation. It
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has been demonstrated that microRNAs can be sorted
for incorporation into exosomes by various mecha-
nisms, and microRNAs such as miR-142-3p and miR-
320 are frequently found to enter exosomes (Zhang
et al., 2015). Thus, such sorting signals may be essen-
tial for retaining microRNAs in the interstitium.
5. Conclusion
Based on the present results, we hypothesize that 61 of
the microRNAs identified originate specifically from
tumor cells and/or from tumor stroma and that these
microRNAs have a high potential for forming blood-
based breast cancer biomarkers for disease detection.
We were able to validate 16 of these microRNAs in an
independent set of serum data obtained from a Chinese
cohort of patients with breast cancer, thus confirming
their potential as diagnostic biomarkers. We advocate
that microRNAs released into the tumor interstitium in
response to cross-talk between malignant cells and TILs
during breast cancer progression may be detected in the
serum of patients with breast cancer and serve as diag-
nostic or prognostic biomarkers.
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Fig. S1. A representative example of the distribution
of TILs that were detected in tumor biopsies based on
HE and IHC staining.
Fig. S2. A Venn diagram represents the microRNAs
that were detected in > 30% of the TIF (n = 457),
NIF (n = 184), and serum (n = 201) samples.
Fig. S3. Hierarchical clustering of the 16 identified bio-
marker candidates.
Fig. S4. Kaplan–Meier survival plots and log-rank test
with P-values for the two clusters of microRNA data.
Doc. S1. Methods.
Table S1. An average expression of Ki67 used for sub-
type estimation and the cutoff of KI67 positivity was
assigned in accordance with the currently accepted cri-
teria (Esposito et al., 2015) and intrinsic subtypes were
assigned as shown in the table, where the luminal B
subtype was divided in two according to HER2-status.
Table S2. An overview of the samples included in the
microRNA profiling.
Table S3. Antibodies used in this study.
Table S4. Spearman Rank Correlation identified
microRNAs correlated between TIF, NIF, Serum and
tumor. P < 0.05 is regarded as significant.
Table S5. Wilcoxon Rank test identified 266 micro-
RNAs with significantly higher abundance in TIF rela-
tively to NIF (FDR < 0.01).
Table S6. 61 microRNAs were identified using the cri-
teria: Up in TIF vs NIF (FDR < 0.01) and expressed
in more than 75% of serum samples.
Table S7. The difference in abundance of the 61 candi-
date microRNAs were tested using student’s t-test and
52 microRNAs showed significantly higher abundance
in tumor mass vs TIF.
Table S8. MicroRNA profiling in serum of Chinese
breast cancer patients.
Table S9. Out of the 457microRNA in TIF, the presence
of TILs and tumor percentage contributed significantly
to the variation of 179microRNAs (FDR < 0.05).
Table S10. Pathway analyses were performed for micro-
RNAs significantly correlated with subgroups of TILs
and adipocytes.
Table S11. Kruskal-Wallis Anova test was performed to
identify microRNAs with differential distribution
between the subgroups.
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